Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant cell arteritis. Read more here/ ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.

Seeking to develop novel medicines for cardiovascular disease, Novartis and ProFound Therapeutics have signed a four-year strategic collaboration. The agreement will allow the partners to combine ...

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new therapeutics for cardiovascular diseases (CVDs), with the deal worth $750m per ...

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was challenged over a potential conflict of interest.

View the latest Novartis AG (NOVN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProFound™ Therapeutics, a company pioneering the expanded human proteome to develop first-in-class medicines for multiple diseases, today announced ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

3 Innovative Ways We’re Reaching Patients, Beyond Our Medicines At Aspen Ideas Health, Novartis is leading conversations about how to address today’s most pressing healthcare concerns. Learn how we’re ...